Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IDYA
SELLIDEAYA Biosciences, Inc. · Healthcare · United States · $3.4B · Avg Vol: $44M/d
COMPANY DESCRIPTION
IDEAYA Biosciences, Inc. is a clinical-stage oncology-focused biotechnology company pioneering the field of synthetic lethality to develop targeted therapeutics. The company's competitive moat is established by its industry-leading pipeline of precision medicine candidates and its proprietary biomarker discovery platform. It operates as a premier biotechnology innovator with strategic development partnerships alongside global pharmaceutical giants.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.9M | 23.4M | 7.0M | 218.7M | 62.5% | 225.3M | 34.1M | 114.6M | -27.6% |
| EPS | -1.42 | -1.96 | -3.36 | -1.28 | — | -1.55 | — | — | — |
| Shares | 48.2M | 65.0M | 86.5M | 87.8M | +82.2% | 96.3M | — | — | — |
| Debt | 3.5M | 2.9M | 19.2M | 27.9M | 100.1% | 28.6M | — | — | — |
| Equity | 349.5M | 621.1M | 1.1B | 1.0B | 43.0% | — | — | — | — |
| Op CF | -87.2M | -115.2M | -247.6M | -71.1M | — | -85.9M | — | — | — |
| Inv CF | -33.4M | -158.5M | -502.6M | 70.0M | — | — | — | — | — |
| Fin CF | 97.2M | 362.7M | 677.6M | 29.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IDYA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc.(you) | $3.4B | 27 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 30 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 27 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 26 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%